Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
29.11.2019 November 2019: Androgen receptor expression and response to chemotherapy
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
08.11.2019 October 2019: Toxicity analysis of neutropenic complications in adjuvant tailored dose-dense chemotherapy from the PANTHER study
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
21.10.2019 ESMO 2019 Congress: Merit Award
Jenny Furlanetto, MD honoured with the Merit Award to the ESMO 2019 Congress
30.09.2019 Save the date: GBG-Jahrestreffen 2020
Das GBG-Jahrestreffen 2020 findet vom 27.-28. Februar in Frankfurt statt.
30.09.2019 Save the date: AGO State of the Art Meeting
Das AGO-Mamma State of the Art Meeting 2020 findet am 29. Februar in Frankfurt statt.
27.09.2019 September 2019: Impact of post-mastectomy radiotherapy (RT) after neoadjuvant chemotherapy (NACT) on survival in breast cancer patients
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
18.09.2019 TAXIS (GBG101) – 1ste Patientin in Deutschland
Am 17. September 2019 wurde die 1ste Patientin in die TAXIS-Studie eingeschlossen.
17.09.2019 GBG Forschung beim ESMO 2019
Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
12.09.2019 August 2019: Results of a pooled analysis from two randomized phase III trials [LEA GBG51 and Cancer and Leukemia Group (CALGB) 40503] evaluating the addition of bevacizumab to endocrine therapy (ET) as first-line treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC)
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
31.07.2019 July 2019: Fatal events occurring during study treatment: a pooled analysis of death cases within GBG led breast cancer trials
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
08.07.2019 Fortbildung Checkpoint-Inihibitoren
Fortbildungsveranstaltung „Behandlung mit Checkpoint-Inihibitoren“ der GBG und des BreastNet Rhein Main am 27. August 2019 von 17:00 – 20:00 Uhr in Frankfurt
04.07.2019 June 2019: Clinical results and biomarker analysis of the randomised phase II GeparNuevo study
We are pleased to inform you that the results of the randomised phase II GeparNuevo (GBG 89) study that aimed to investigate the addition of durvalumab, a human monoclonal antibody targeting programmed cell death ligand-1 (PD-L1) to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) have been published in the Annals of Oncology.
03.06.2019 May 2019: Long-term outcomes of the GeparSepto study
The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.
27.05.2019 GBG Studien beim ASCO 2019: Ein Erfolg auf ganzer Linie
Auf dem ASCO-Kongress 2019 konnten wir einige Ergebnisse und neue Studienkonzepte der GBG vorestellen.
22.05.2019 May 2019: Mutational landscape and therapy response in GeparSepto trial
Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.
07.05.2019 AURORA: inital results presented
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
02.05.2019 GBG Research at ESMO Breast Cancer 2019
Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.
10.04.2019 April 2019: Results from E-VITA trial conducted with HER2-positive metastatic breast cancer patients
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer have been published in the Anticancer Drugs.
01.03.2019 March 2019: Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.
01.02.2019 February 2019: Results of the GeparOcto trial
We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.
